Sparc Life

Mumbai, India Founded: 2006 • Age: 20 yrs Listed
Therapies for cancer and inflammatory diseases are developed.
Request Access
Report Incorrect Data
Page last updated

About Sparc Life

Sparc Life is a publicly listed company based in Mumbai (India) founded in 2006. Therapies for cancer and inflammatory diseases are developed. The company has 512 employees. Its chief executive, as recorded, is Anil Raghavan. Its Indian entity Sun Pharma Advanced Research Company Limited reported revenue of ₹1,890 Cr. Sparc Life offers products and services including Vodobatinib, Vibozilimod, SBO-154, and SCD-153. Its focus areas include Diversified Pharmaceuticals and Drugs.

Company details

Sun Pharma Advanced Research Company is developing therapies for cancer and inflammatory diseases. The company was formed as a spin-out from Sun Pharma for all their innovative drug discovery. Their first lead candidate, Sun K706, is a tyrosine kinase inhibitor, intended for the treatment of chronic myelogenous leukemia on the most resistant form of mutation in leukemic cells - T315I mutation. The second candidate is Sun 0597, a novel, safe non-systemic glucocorticoid to treat inflammations of the airway, skin, eye, and gastrointestinal tract. All other candidates are in preclinical stages.

  • Headquarters Mumbai, India
  • Employees 512
  • Stage Public
  • Sectors
    Healthcare
  • Website sparc.life
  • Social LinkedIn X
  • Legal Name Sun Pharma Advanced Research Co. Ltd.
Operational Areas
Healthcare → Pharmaceuticals & Distribution
Key Metrics
  • Market Cap
    ₹5,938 Cr

    SPARC · NSE

  • Share Price
    ₹176.46

    -3.56% today

  • Revenue
    ₹1,879 Cr

    FY 2025-26 · +2518.3% YoY

  • EBITDA
    ₹1,586 Cr

    Margin 84.4%

  • Net Profit
    ₹1,565 Cr

    FY 2025-26 · +557.0% YoY

  • P/E (TTM)
    3.7x

    P/B 4.4x

  • ROE
    164.5%

    ROCE 110.8%

  • Debt / Equity
    0.74

    Interest cover 2.2x

  • Employee Count
    512

Products & Services of Sparc Life

Sparc Life offers a comprehensive portfolio of products and services, including Vodobatinib, Vibozilimod, SBO-154, and SCD-153.

Vodobatinib
Drug

BCR-ABL inhibitor for treating refractory CML in oncology.

Vibozilimod
Drug

Selective S1PR1 agonist for psoriasis and atopic dermatitis.

SBO-154
Antibody Drug Conjugate

Anti-MUC-1 ADC targeting multiple tumors in oncology.

SCD-153
Therapeutic Agent

Undisclosed compound for treating alopecia areata.

Funding Insights of Sparc Life

  • Total Rounds 1

All 1 funding rounds of Sparc Life with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2021Post-IPO––
–

Board of directors of Sun Pharma Advanced Research Company Limited (Sparc Life)

Sun Pharma Advanced Research Company Limited is the primary company behind Sparc Life. The board of Sun Pharma Advanced Research Company Limited currently have 6 directors; the longest-serving is Dilip Shantilal Shanghvi, appointed in 2006. 17 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Dilip Shantilal Shanghvi
DIN 00005588
Director01 Mar 200620 yrs 8 moSun Pharma Advanced Research Company Limited
Rajamannar Thennati
DIN 01415412
Director04 Jun 200719 yrs 4 moSun Pharma Advanced Research Company Limited
Robert Jay Spiegel
DIN 08739625
Director01 Jun 20206 yrs 5 moSun Pharma Advanced Research Company Limited
Vidhi Dilip Shanghvi
DIN 06497350
Director15 Jul 20242 yrs 3 moSun Pharma Advanced Research Company Limited
Venkateswarlu Jasti
DIN 00278028
Director19 May 20251 yr 5 moSun Pharma Advanced Research Company Limited
Rekha Gopal Warriar
DIN 08152356
Director19 May 20251 yr 5 moSun Pharma Advanced Research Company Limited

People of Sparc Life

23 people are tracked at Sparc Life (11 in leadership, 12 in team); the tracked headcount is 512.

NameRoleGroup
Anil Raghavan
CEOLeadership
Venkata Palle
Executive Vice President And Global Head Of Drug Discovery And Preclinical DevelopmentLeadership
Vikram Ramanathan
Head Preclinical DevelopmentLeadership
Nitin Damle
Chief Innovation OfficerLeadership
Trinadha Rao Chitturi
Sr. Vice–president Medicinal ChemistryLeadership
Kathleen M. Giacomini
Head Preclinical DevelopmentLeadership
Zach W. Hall
Head Preclinical DevelopmentLeadership
Shanta Gupta
Chief Human Resource OfficerLeadership
Shravanti Bhowmik
Head Operations ManagementLeadership
Anup Rathi
Chief Financial OfficerLeadership
Jaydeep Issrani
Senior General Manager - Business Development, Corporate Communication And Investor RelationsLeadership
Vikas Nema
Senior ManagerTeam
Rajashree Kadam
Manager-2-formulation DevelopmentTeam
Sneha Sonar
Senior Manager Human ResourcesTeam
Sameer Kulkarni
Sr. Manager - Business DevelopmentTeam
Sharad More
Senior Manager AdministrationTeam
Rajesh Gupta
Group LeaderTeam
Divyesh Chauhan
Sr ExecutiveTeam
Patricia Zayas
Executive AssistantTeam
Abhishek Kumar Jain
Senior Manager 1 (drug Delivery)Team

3 more people are available in the full profile.

Premium access

Complete people profiles for Sparc Life

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Sparc Life

Sparc Life is a publicly listed company on the NSE with ticker symbol SPARC in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date18 Jul 2007
  • Listed onNSE: SPARC · BSE: 532872
  • Listed entitySun Pharma Advanced Research Co. Ltd.
  • Exchange sectorHealth technology
  • ISININE232I01014
  • Share price₹193.60 (+2.41% on the day) · 2026-10-14
  • Market capitalisation₹6,124 Cr
  • Price to earnings4.0
  • EPS (diluted, trailing year)₹48.82
  • Volume (last session)993,409

Financials of Sparc Life

Exchange-reported figures of Sun Pharma Advanced Research Company Limited, the listed company behind Sparc Life (NSE: SPARC).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,879 Cr
+2518.3% YoY
EBITDA
₹1,586 Cr
+591.0% YoY
Profit After Tax
₹1,565 Cr
+557.0% YoY
Net Worth
₹1,339 Cr
+717.1% YoY
Total Assets
₹1,974 Cr
+1501.6% YoY
Total Debt
₹559 Cr
+108.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Income statement
Revenue1,87971.7775.55239
Revenue growth+2518.3%-5.0%-68.4%-
EBITDA1,586(323)(402)(214)
EBITDA margin+84.4%-450.2%-532.2%-89.7%
Profit before tax1,553(343)(387)(223)
Net profit1,565(343)(388)(222)
Net profit margin+83.3%-477.3%-513.3%-93.2%
EPS (₹)47.86(10.55)(11.93)(6.86)
Balance sheet
Total assets1,974123300654
Net worth1,339(217)126513
Total debt55926961.1515.67
Cash & bank1.161.96155112
Net working capital1,666(186)53.01(11.82)
Cash flow
Cash from operations(239)(360)(429)(69.12)
Cash from investing(23.42)158392(548)
Cash from financing26119942.41617
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue39.921,8538.457.869.6427.1914.9112.86
Revenue growth (YoY)+314.1%+6715.8%-43.3%-38.9%-42.7%---
Other income23.661.800.000.019.140.000.190.04
EBITDA(34.00)1,773(69.00)(65.72)(52.08)(53.18)(73.69)(103)
EBITDA margin-85.2%--816.6%-836.1%-540.2%-195.6%-494.2%-800.2%
Depreciation2.202.402.572.562.682.953.143.16
Interest8.1311.648.787.526.194.542.801.14
Profit before tax(20.67)1,761(80.35)(75.79)(51.81)(60.67)(79.44)(107)
Tax0.11(0.38)0.070.060.06(0.90)0.070.16
Net profit(20.78)1,761(80.42)(75.85)(51.87)(59.77)(79.51)(107)
EPS (₹)(0.64)54.27(2.48)(2.34)(1.60)(1.84)(2.45)(3.31)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,87971.7775.5523913725376.81
Revenue growth+2518.3%-5.0%-68.4%+74.0%-45.7%+229.3%-
EBITDA1,586(327)(404)(214)(187)(135)(310)
EBITDA margin+84.4%-456.0%-534.5%-89.7%-136.1%-53.4%-403.6%
Profit before tax1,552(345)(388)(223)(203)(151)(312)
Net profit1,564(345)(389)(222)(208)(151)(319)
Net profit margin+83.3%-481.1%-514.5%-93.2%-151.8%-59.9%-414.9%
EPS (₹)47.83(10.64)(11.96)(6.86)(7.48)(5.77)(11.92)
Balance sheet
Total assets1,96911629165418511697.75
Net worth1,334(221)12551331.23(168)(18.63)
Total debt55926556.2315.6779.2123666.92
Cash & bank0.321.191551121.239.310.46
Net working capital1,662(188)49.73(11.83)(35.15)(57.00)(116)
Cash flow
Cash from operations(239)(362)(429)(69.12)(208)(152)(211)
Cash from investing(23.51)158391(548)(29.17)1.56155
Cash from financing26220142.8061722915955.46
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue39.921,8538.457.869.6427.1914.9112.86
Revenue growth (YoY)+314.1%+6715.8%-43.3%-38.9%-42.7%---
Other income23.661.800.000.019.020.000.190.04
Total expenses74.2380.2877.6873.7561.9781.1189.29117
EBITDA(34.31)1,773(69.23)(65.89)(52.33)(53.92)(74.38)(104)
EBITDA margin-85.9%--819.3%-838.3%-542.8%-198.3%-498.9%-807.5%
Depreciation2.202.402.562.572.542.552.752.77
Interest8.1311.648.787.526.184.512.771.11
Profit before tax(20.98)1,761(80.57)(75.97)(52.03)(60.98)(79.71)(108)
Tax0.000.000.000.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 31 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue39.921,8538.457.869.6427.1914.9112.86
Revenue growth (YoY)+314.1%+6715.8%-43.3%-38.9%-42.7%---
Other income23.661.800.000.019.140.000.190.04
EBITDA(34.00)1,773(69.00)(65.72)(52.08)(53.18)(73.69)(103)
EBITDA margin-85.2%--816.6%-836.1%-540.2%-195.6%-494.2%-800.2%
Depreciation2.202.402.572.562.682.953.143.16
Interest8.1311.648.787.526.194.542.801.14
Profit before tax(20.67)1,761(80.35)(75.79)(51.81)(60.67)(79.44)(107)
Tax0.11(0.38)0.070.060.06(0.90)0.070.16
Net profit(20.78)1,761(80.42)(75.85)(51.87)(59.77)(79.51)(107)
EPS (₹)(0.64)54.27(2.48)(2.34)(1.60)(1.84)(2.45)(3.31)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Revenue1,87971.7775.55239
Revenue growth+2518.3%-5.0%-68.4%-
Other income10.951.7929.4710.88
Total expenses293395478453
Employee cost118154142107
EBITDA1,586(323)(402)(214)
EBITDA margin+84.4%-450.2%-532.2%-89.7%
Depreciation10.2112.3912.5111.77
Interest34.139.041.697.63
Profit before tax1,553(343)(387)(223)
Tax(0.20)(0.28)0.380.00
Net profit1,565(343)(388)(222)
Net profit margin+83.3%-477.3%-513.3%-93.2%
EPS (₹)47.86(10.55)(11.93)(6.86)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Equity & liabilities
Share capital32.4532.4532.4532.45
Reserves & surplus1,306(249)93.30480
Shareholders' funds (net worth)1,339(217)126513
Minority interest0.000.000.000.00
Secured loans45615847.000.05
Unsecured loans10311114.1515.62
Total debt55926961.1515.67
Total liabilities1,974123300654
Assets
Gross block144158157146
Net block85.3298.76108106
Capital work in progress71.7154.1543.7927.00
Investments0.000.001.80291
Inventories0.000.000.000.00
Sundry debtors8.2716.0615.5332.71
Cash & bank balances1.161.96155112
Loans & advances1,8538.1896.7219.78
Total current assets1,86226.20268164
Total current liabilities196212215176
Net working capital1,666(186)53.01(11.82)
Total assets1,974123300654
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Opening cash1.965.330.581.22
Net cash from operating activities(239)(360)(429)(69.12)
Net cash from investing activities(23.42)158392(548)
Net cash from financing activities26119942.41617
Net change in cash(0.81)(3.37)4.75(0.64)
Closing cash1.161.96155112
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Growth
Sales growth+2518.3%-5.0%-68.4%-
EBITDA growth+591.0%+19.6%-87.8%-
PBT growth+9998.0%+11.4%-73.8%+9997.0%
Net income growth+557.0%+11.7%-74.3%-
Revenue CAGR (3Y)+98.9%---
Profitability & leverage
Net income margin+82.7%-477.2%-512.5%-93.2%
Return on capital employed+110.8%0.0%0.0%0.0%
Return on net worth+164.5%0.0%0.0%0.0%
Debt / equity0.740.000.120.03
Long-term debt / equity0.100.000.040.02
Interest cover2.17-2.69-0.41-3.38
Efficiency & per share
Fixed asset turnover12.440.460.501.63
Inventory turnover0.000.000.000.00
Debtors turnover154.474.543.137.30
EPS (₹)47.86(10.55)(11.93)(6.86)
Dividend per share (₹)0.000.000.000.00
Book value per share (₹)41.25(6.68)3.8815.80
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue39.921,8538.457.869.6427.1914.9112.86
Revenue growth (YoY)+314.1%+6715.8%-43.3%-38.9%-42.7%---
Other income23.661.800.000.019.020.000.190.04
Total expenses74.2380.2877.6873.7561.9781.1189.29117
EBITDA(34.31)1,773(69.23)(65.89)(52.33)(53.92)(74.38)(104)
EBITDA margin-85.9%--819.3%-838.3%-542.8%-198.3%-498.9%-807.5%
Depreciation2.202.402.562.572.542.552.752.77
Interest8.1311.648.787.526.184.512.771.11
Profit before tax(20.98)1,761(80.57)(75.97)(52.03)(60.98)(79.71)(108)
Tax0.000.000.000.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,87971.7775.5523913725376.81
Revenue growth+2518.3%-5.0%-68.4%+74.0%-45.7%+229.3%-
Other income10.831.7929.4710.886.845.419.76
Total expenses294399479453324388387
Employee cost10210911910798.3191.5993.09
EBITDA1,586(327)(404)(214)(187)(135)(310)
EBITDA margin+84.4%-456.0%-534.5%-89.7%-136.1%-53.4%-403.6%
Depreciation10.0710.8312.1311.7710.1610.929.48
Interest34.128.911.667.6313.3310.652.67
Profit before tax1,552(345)(388)(223)(203)(151)(312)
Tax0.000.000.000.000.000.000.00
Net profit1,564(345)(389)(222)(208)(151)(319)
Net profit margin+83.3%-481.1%-514.5%-93.2%-151.8%-59.9%-414.9%
EPS (₹)47.83(10.64)(11.96)(6.86)(7.48)(5.77)(11.92)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital32.4532.4532.4532.4527.1926.2126.21
Reserves & surplus1,301(253)92.40480(230)(194)(44.84)
Shareholders' funds (net worth)1,334(221)12551331.23(168)(18.63)
Secured loans45615847.000.0575.001505.83
Unsecured loans1031079.2315.624.2186.3861.09
Total debt55926556.2315.6779.2123666.92
Total liabilities1,96911629165418511697.75
Assets
Gross block144153152146133123136
Net block85.3295.3310310691.8790.56104
Capital work in progress71.7154.1543.7927.0026.375.2332.07
Investments0.430.422.2229111.666.438.49
Inventories0.000.000.000.000.000.000.00
Sundry debtors8.2716.0615.5332.7127.7417.5816.05
Cash & bank balances0.321.191551121.239.310.46
Loans & advances1,8538.0174.0119.7730.5329.8042.19
Total current assets1,86125.2624516459.5056.6958.70
Total current liabilities19921319517694.65114175
Net working capital1,662(188)49.73(11.83)(35.15)(57.00)(116)
Total assets1,96911629165418511697.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1.195.060.581.229.300.350.35
Net cash from operating activities(239)(362)(429)(69.12)(208)(152)(211)
Net cash from investing activities(23.51)158391(548)(29.17)1.56155
Net cash from financing activities26220142.8061722915955.46
Net change in cash(0.87)(3.87)4.48(0.64)(8.08)8.950.00
Closing cash0.321.191551121.239.310.46
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+2518.3%-5.0%-68.4%+74.0%-45.7%+229.3%-
EBITDA growth+584.5%+19.0%-88.6%-14.6%-38.3%+56.5%-
PBT growth+9998.0%+11.1%-74.4%-9.4%-34.6%+51.6%-114.8%
Net income growth+553.1%+11.2%-74.7%-6.8%-37.6%+52.5%-
Revenue CAGR (3Y)+98.9%-19.4%-33.2%+46.0%-9.1%+47.9%-24.9%
EBITDA CAGR (3Y)-+20.6%+44.1%-11.6%+7.3%-17.8%+36.2%
Profitability & leverage
Net income margin+82.6%-481.0%-513.7%-93.2%-148.2%-59.8%-406.7%
Return on capital employed+111.1%0.0%0.0%0.0%0.0%0.0%0.0%
Return on net worth+164.8%0.0%0.0%0.0%0.0%0.0%0.0%
Debt / equity0.740.000.110.170.000.000.25
Long-term debt / equity0.100.000.030.030.000.000.03
Interest cover2.17-2.64-0.40-3.38-6.77-7.30-0.84
Efficiency & per share
Fixed asset turnover12.670.470.511.711.071.960.71
Inventory turnover0.000.000.000.000.000.000.00
Debtors turnover154.474.543.137.906.0615.045.86
EPS (₹)47.83(10.64)(11.96)(6.86)(7.48)(5.77)(11.92)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)41.09(6.80)3.8515.80(7.47)(6.42)(0.71)

Timeline of Sparc Life

3 dated milestones of Sparc Life across 15 years, from founding to its latest funding, stage changes and deals.

  1. Founded Sparc Life is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round.

Web traffic of Sparc Life

Websites that share an audience with Sparc Life (sparc.life).

Similar websites

Websites whose visitors overlap most with Sparc Life. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Zenon Healthcare
zenonhealthcare.com
100%
1.2K#12,140,733View details
Baroque Pharma
baroquepharma.com
96%
View details
Swiss Pharma
swisspharma.in
96%
1.3K#10,147,211View details
zivonlifecare.com
zivonlifecare.com
93%
#9,678,407–
Concord Biotech
concordbiotech.com
89%
3.7K#4,215,278View details
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 6 similar websites and full traffic analytics for Sparc Life

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 6 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Sparc Life

Zydus, Sun Pharma lead India pharma growth in July; Sun gains semaglutide share: Nomura
Moneycontrol • 2 months ago
Delhi HC directs Sun Pharma to take permission before launching semaglutide
Mint • 2 months ago
SPARC: Q1 FY27 saw normalized revenue and a net loss following a major one-time PRV sale in Q4
Quartr • 2 months ago
Buy Sun Pharma; target of Rs 2310: Motilal Oswal
Moneycontrol • 3 months ago
Sun Pharma to Consider Quarterly Results Tomorrow; Shares Close Marginally Higher in Previous Session
Moneycontrol • 3 months ago
Sun Pharma Advanced Research Appoints Anil Raghavan As MD And CEO Effective August 11
Reuters • 3 months ago
Indian drugmakers struggle to sell in China as FY26 exports see double-digit drop to $287 million
Moneycontrol • 4 months ago
State Bank of India plans $1 billion funding for Sun Pharma's US Deal - Bloomberg News
Reuters • 4 months ago
Trade Spotlight: How should you trade SPARC, Gland Pharma, Techno Electric, GE Power India, Supriya Lifescience, and others on May 25?
Moneycontrol • 5 months ago
Sun Pharma Advanced Research Says Ocuvex Therapeutics Gets Complete Response Letter For PDP-716 NDA
Reuters • 5 months ago
Premium access

Complete news archive for Sparc Life

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sparc Life

Sparc Life was founded in 2006 and raised its 1st funding round 15 years after it was founded.

Sparc Life is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Anil Raghavan is the CEO of Sparc Life, as recorded in our data.

Sparc Life has 512 employees.

The primary company behind Sparc Life, Sun Pharma Advanced Research Company Limited, reported revenue of ₹1,890 Cr for FY 2026, up 2518% year on year.

Sun Pharma Advanced Research Company is developing therapies for cancer and inflammatory diseases. The company was formed as a spin-out from Sun Pharma for all their innovative drug discovery. Their first lead candidate, Sun K706, is a tyrosine kinase inhibitor, intended for the treatment of chronic myelogenous leukemia on the most resistant form of mutation in leukemic cells - T315I mutation. The second candidate is Sun 0597, a novel, safe non-systemic glucocorticoid to treat inflammations of the airway, skin, eye, and gastrointestinal tract. All other candidates are in preclinical stages.

Sparc Life offers Vodobatinib, Vibozilimod, SBO-154, and SCD-153.

Yes, Sparc Life is publicly traded on NSE under the ticker symbol SPARC.

Sparc Life operates through Sun Pharma Advanced Research Company Limited.

The legal entities of Sparc Life currently have 9 directors, including Rajamannar Thennati, Robert Jay Spiegel, Dilip Shantilal Shanghvi and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available